carpal tunnel syndrome. Mononeuropathies of upper limb
Conditions
Interventions
Intervention 1: Single injection of 1 ml of PRP with 0.5 ml lidocain 1% in carpal tunnel and prefabricated hand wrist splint in neutral position for CTS. Intervention 2: Prefabricated hand wrist spli
Treatment - Drugs
Treatment - Other
Single injection of 1 ml of PRP with 0.5 ml lidocain 1% in carpal tunnel and prefabricated hand wrist splint in neutral position for CTS
Prefabricated hand wrist splint in neutral position for CTS
Sponsors
Vice chancellor for research,Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
20 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: patient with mild and moderate CTS confirmed by the presence of one or more of the following standard electrophysiological criteria: 1- prolonged distal motor latency (DML) (abnormal response is more than 4.2 millisecond) of Median nerve and 2- prolonged antidromic distal sensory latency (DSL) to the third digit (abnormal response is more than 3.6 millisecond); Exclusion criteria: Pregnancy; Severe degree CTS; Background metabolic diseases such as: diabetes mellitus; hypothyroidism; rheumatoid arthritis; Previous history of corticosteroid injection in Carpal Tunnel Syndrome; Severe atrophy of thenar muscles; cervical radiculopathy or significant polyneuropathy; Unwillingness to participate in the present study; patient younger than 20 or older than 65 years old; history or presence of cancer or malignant disorders; presence of immunosuppressive, autoimmune and platelet disorders; treatment with anticoagulant and anti-platelet medications 10 days before injection; use of NSAIDs 2 days before injection; use of systemic corticosteroids 2 weeks before PRP injections; hemoglobin measures of less than 12 g/dl and platelet counts of less than 150,000 per micro liter
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain. Timepoint: at the beginning and after 10 weeks of injection or 10 weeks after starting using splint. Method of measurement: Visual Analog Scale, that is from 0-10 and zero (0) means that you did not have any pain and ten (10) means that you had the worst pain imaginable. | — |
Secondary
| Measure | Time frame |
|---|---|
| Median CMAP distal latency. Timepoint: at the beginning and after 10 weeks of injection or 10 weeks after starting using splint. Method of measurement: Electrodiagnostic study.;Symptom severity. Timepoint: at the beginning and after 10 weeks of injection or 10 weeks after starting using splint. Method of measurement: Boston/Levine symptome severity scale.;Median SNAP peak latency. Timepoint: at the beginning and after 10 weeks of injection or 10 weeks after starting using splint. Method of measurement: Electrodiagnostic study.;Functional Status. Timepoint: at the beginning and after 10 weeks of injection or 10 weeks after starting using splint. Method of measurement: boston questionaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactLeila Bagherzadeh
Shahid Beheshti Univeraity of Medical Sciences
Outcome results
None listed